PL1670514T3 - Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II - Google Patents

Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II

Info

Publication number: PL1670514T3
Authority: PL; Poland
Prior art keywords: inhibitor; topoisomerase; histone deacetylase; antitumor agent; deacetylase inhibitor
Prior art date: 2003-09-25

Application number

PL04773539T

Other languages

English (en)

Inventor

Yoshinori Naoe

Yuka Sasakawa

Original Assignee

Astellas Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-25

Filing date

2004-09-24

Publication date

2010-11-30

2004-09-24 Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc

2010-11-30 Publication of PL1670514T3 publication Critical patent/PL1670514T3/pl

Links

229940124087 DNA topoisomerase II inhibitor Drugs 0.000 title abstract 2
239000000317 Topoisomerase II Inhibitor Substances 0.000 title abstract 2
239000002246 antineoplastic agent Substances 0.000 title 1
229940121372 histone deacetylase inhibitor Drugs 0.000 title 1
239000003276 histone deacetylase inhibitor Substances 0.000 title 1
150000003839 salts Chemical class 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 abstract 1
229960002550 amrubicin Drugs 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Compounds Of Unknown Constitution (AREA)

PL04773539T 2003-09-25 2004-09-24 Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II PL1670514T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP2003334340		2003-09-25
JP2003344315		2003-10-02
PCT/JP2004/014451 WO2005030239A2 (en)	2003-09-25	2004-09-24	Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
EP04773539A EP1670514B1 (en)	2003-09-25	2004-09-24	Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor

Publications (1)

Publication Number	Publication Date
PL1670514T3 true PL1670514T3 (pl)	2010-11-30

Family

ID=34380371

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL04773539T PL1670514T3 (pl)	2003-09-25	2004-09-24	Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II
PL10163527T PL2263694T3 (pl)	2003-09-25	2004-09-24	Środek przeciwnowotworowy zawierający FK228 jako inhibitor deacetylazy histonowej i doksorubicynę jako inhibitor topoizomerazy II

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL10163527T PL2263694T3 (pl)	2003-09-25	2004-09-24	Środek przeciwnowotworowy zawierający FK228 jako inhibitor deacetylazy histonowej i doksorubicynę jako inhibitor topoizomerazy II

Country Status (14)

Country	Link
US (1)	US7314862B2 (pl)
EP (2)	EP1670514B1 (pl)
JP (1)	JP4779971B2 (pl)
AT (1)	ATE471740T1 (pl)
CA (1)	CA2540108A1 (pl)
CY (1)	CY1114359T1 (pl)
DE (1)	DE602004027824D1 (pl)
DK (1)	DK2263694T3 (pl)
ES (2)	ES2425083T3 (pl)
MX (1)	MXPA06003222A (pl)
PL (2)	PL1670514T3 (pl)
PT (1)	PT2263694E (pl)
SI (1)	SI2263694T1 (pl)
WO (1)	WO2005030239A2 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4238728B2 (ja) *	2001-08-21	2009-03-18	アステラス製薬株式会社	ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
US8673888B2 (en) *	2002-04-05	2014-03-18	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Depsipeptide for therapy of kidney cancer
US7154002B1 (en)	2002-10-08	2006-12-26	Takeda San Diego, Inc.	Histone deacetylase inhibitors
EP1595952A4 (en) *	2003-02-19	2008-05-21	Astellas Pharma Inc	METHOD FOR EVALUATING THE ANTITUMOR EFFECT OF A HISTONE DEACETYLASE INHIBITOR
US7381825B2 (en) *	2003-03-17	2008-06-03	Takeda San Diego, Inc.	Histone deacetylase inhibitors
ES2425083T3 (es)	2003-09-25	2013-10-11	Astellas Pharma Inc.	Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
US20050159470A1 (en) *	2003-12-19	2005-07-21	Syrrx, Inc.	Histone deacetylase inhibitors
US20050137234A1 (en) *	2003-12-19	2005-06-23	Syrrx, Inc.	Histone deacetylase inhibitors
US7951780B2 (en) *	2004-02-25	2011-05-31	Astellas Pharma Inc.	Antitumor agent
EP1824831A2 (en) *	2004-12-16	2007-08-29	Takeda San Diego, Inc.	Histone deacetylase inhibitors
EP1896436A2 (en) *	2005-05-11	2008-03-12	Takeda San Diego, Inc.	Histone deacetylase inhibitors
EA200800321A1 (ru) *	2005-07-14	2008-06-30	Такеда Сан Диего, Инк.	Ингибиторы гистондеацетилазы
US7943568B2 (en) *	2005-09-30	2011-05-17	The Ohio State University Research Foundation	Antitumor agents
US20070129290A1 (en) *	2005-11-18	2007-06-07	Or Yat S	Metabolite derivatives of the HDAC inhibitor FK228
JP2009525955A (ja) *	2006-01-13	2009-07-16	タケダサンディエゴインコーポレイテッド	ヒストンデアセチラーゼ阻害剤
EP2012801A4 (en)	2006-04-24	2009-08-05	Gloucester Pharmaceuticals Inc	GEMCITABINE COMBINATION THERAPY
US8957027B2 (en) *	2006-06-08	2015-02-17	Celgene Corporation	Deacetylase inhibitor therapy
US9408816B2 (en) *	2006-12-26	2016-08-09	Pharmacyclics Llc	Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
AU2007342028B2 (en) *	2006-12-29	2013-06-13	Celgene Corporation	Purifiction of romidepsin
CN101687010A (zh) *	2006-12-29	2010-03-31	格洛斯特制药公司	制备Romidepsin
US8034768B2 (en) *	2007-06-22	2011-10-11	Board Of Regents, The University Of Texas System	Composition and method for the treatment of diseases affected by histone deacetylase inhibitors
US20110021517A1 (en) *	2008-02-26	2011-01-27	Nerviano Medical Sciences S.R.L.	Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
NZ605526A (en)	2010-07-12	2015-04-24	Celgene Corp	Romidepsin solid forms and uses thereof
US8859502B2 (en)	2010-09-13	2014-10-14	Celgene Corporation	Therapy for MLL-rearranged leukemia
JP6330118B2 (ja)	2011-09-13	2018-05-30	ファーマサイクリックスエルエルシー	ベンダムスチンと組み合わせたヒストンデアセチラーゼ阻害剤の製剤とその使用
AU2013202506B2 (en)	2012-09-07	2015-06-18	Celgene Corporation	Resistance biomarkers for hdac inhibitors
US20150283159A1 (en) *	2012-11-01	2015-10-08	Microbial Chemistry Research Foundation	Anticancer agent, and combination use anticancer agent
AU2013202507B9 (en)	2012-11-14	2015-08-13	Celgene Corporation	Inhibition of drug resistant cancer cells
NZ630311A (en)	2013-12-27	2016-03-31	Celgene Corp	Romidepsin formulations and uses thereof
CN116327887B (zh) *	2023-04-24	2023-11-03	南京捷因诊断技术有限公司	一种lsd1抑制剂作为抗肿瘤药物的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US574455A (en) *		1897-01-05		Switch-lock
US486379A (en) *		1892-11-15		Hame-tug
US3997633A (en) *	1975-06-24	1976-12-14	Max Leva	Contact towers with leak-proof support of improved plate subassembly
US4315851A (en) *	1978-12-29	1982-02-16	Kureha Kagaku Kogyo Kabushiki Kaisha	Pharmaceutical composition having antitumor activity
US4348388A (en) *	1980-04-02	1982-09-07	G.D. Searle & Co.	11-Amino-11-deoxydaunorubicin and analogs
GB8426672D0 (en) *	1984-10-22	1984-11-28	Erba Farmitalia	Pharmaceutical compositions
US4950755A (en) *	1985-08-12	1990-08-21	Ohio State University	Bis(morpholinomethyl) derivative of 1,2-bis(dioxopiperizinyl)propane
US5242901A (en) *	1988-01-27	1993-09-07	New York University	Reduction of anthracycline induced cardiotoxicity
GB8817743D0 (en)	1988-07-26	1988-09-01	Fujisawa Pharmaceutical Co	Fr901228 substance & preparation thereof
WO1991018599A2 (de) *	1990-05-26	1991-12-12	Byk Gulden Lomberg Chemische Fabrik Gmbh	1,4-dihydropyridine zur anwendung bei der überwindung von arzneimittelresistenzen
US5620961A (en) *	1994-04-25	1997-04-15	Markovic; Nenad S.	Fructose ester-β-cyclodextrin complexes and processes for making and using same
US5919816A (en) *	1994-11-14	1999-07-06	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
US6020373A (en) *	1995-10-20	2000-02-01	Eastern Virginia Medical School	Chelate derivatives as protectors against tissue injury
US5780054A (en) *	1996-01-17	1998-07-14	University Of British Columbia	Methods for increasing the circulation half-life of protein-based therapeutics
US6451784B1 (en) *	1996-12-30	2002-09-17	Battellepharma, Inc.	Formulation and method for treating neoplasms by inhalation
AU741439B2 (en) *	1996-12-30	2001-11-29	Battelle Memorial Institute	Formulation and method for treating neoplasms by inhalation
US7229841B2 (en) *	2001-04-30	2007-06-12	Cytimmune Sciences, Inc.	Colloidal metal compositions and methods
US6286513B1 (en) *	1998-10-22	2001-09-11	Jessie L. Au	Methods for treating superficial bladder carcinoma
US6197809B1 (en) *	1998-12-23	2001-03-06	Ardenia Investments Ltd.	Compounds for the treatment of cancer
US20030144570A1 (en) *	1999-11-12	2003-07-31	Angiotech Pharmaceuticals, Inc.	Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
EP1748046A3 (en) *	1999-11-23	2007-08-22	Methylgene, Inc.	Inhibitors of histone deacetylase
US6593308B2 (en) *	1999-12-03	2003-07-15	The Regents Of The University Of California	Targeted drug delivery with a hyaluronan ligand
CN1414971A (zh) *	1999-12-08	2003-04-30	埃克斯西特治疗公司	用作免疫抑制剂的缩肽及其同类物
US20020028237A1 (en) *	2000-04-20	2002-03-07	Colbern Gail T.	Method for reducing toxicity of a cytotoxic agent
ATE425177T1 (de) *	2000-07-17	2009-03-15	Astellas Pharma Inc	Reduziertes fk228 und seine verwendung
CZ2003837A3 (cs) *	2000-09-22	2004-12-15	Bristol-Myers Squibb Company	Způsob pro snížení toxicity při kombinovaných chemoterapiích
AU2001290636A1 (en) *	2000-09-22	2002-04-02	Bristol-Myers Squibb Company	Method for reducing toxicity of combined chemotherapies
WO2002045717A1 (en) *	2000-12-06	2002-06-13	Tularik Inc.	Lometrexol combination therapy
US20030099960A1 (en) *	2001-01-26	2003-05-29	The University Of Chicago	Compositions and methods for optimizing UGT2B7 substrate dosings and for predicting UGT2B7 substrate toxicity
ATE450265T1 (de) *	2001-03-23	2009-12-15	Shire Canada Inc	Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
US6905669B2 (en) *	2001-04-24	2005-06-14	Supergen, Inc.	Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
JP4238728B2 (ja) *	2001-08-21	2009-03-18	アステラス製薬株式会社	ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
US8673888B2 (en) *	2002-04-05	2014-03-18	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Depsipeptide for therapy of kidney cancer
BR0310026A (pt) *	2002-05-17	2005-02-15	Aventis Pharma Sa	Uso de docetaxel/doxorrubicina/ciclofosfamida em terapia adjuvante de câncer de mama e ovariano
US20040136905A1 (en) *	2002-10-15	2004-07-15	Kent Thomas B.	Magnetically guided particles for radiative therapies
US20040152632A1 (en) *	2002-11-06	2004-08-05	Wyeth	Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
WO2004064727A2 (en) *	2003-01-16	2004-08-05	Georgetown University	Method of cancer treatment using hdac inhibitors
MXPA05012464A (es)	2003-05-21	2006-01-30	Novartis Ag	Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
PE20050206A1 (es) *	2003-05-26	2005-03-26	Schering Ag	Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
SI2238982T1 (sl) *	2003-06-27	2013-01-31	Astellas Pharma Inc.	Terapevtsko sredstvo za mehkotkivni sarkom
ES2425083T3 (es)	2003-09-25	2013-10-11	Astellas Pharma Inc.	Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
US7951780B2 (en) *	2004-02-25	2011-05-31	Astellas Pharma Inc.	Antitumor agent

2004
- 2004-09-24 ES ES10163527T patent/ES2425083T3/es not_active Expired - Lifetime
- 2004-09-24 EP EP04773539A patent/EP1670514B1/en not_active Expired - Lifetime
- 2004-09-24 ES ES04773539T patent/ES2344899T3/es not_active Expired - Lifetime
- 2004-09-24 CA CA002540108A patent/CA2540108A1/en not_active Abandoned
- 2004-09-24 PT PT101635274T patent/PT2263694E/pt unknown
- 2004-09-24 MX MXPA06003222A patent/MXPA06003222A/es active IP Right Grant
- 2004-09-24 SI SI200432064T patent/SI2263694T1/sl unknown
- 2004-09-24 EP EP10163527.4A patent/EP2263694B1/en not_active Expired - Lifetime
- 2004-09-24 PL PL04773539T patent/PL1670514T3/pl unknown
- 2004-09-24 DK DK10163527.4T patent/DK2263694T3/da active
- 2004-09-24 PL PL10163527T patent/PL2263694T3/pl unknown
- 2004-09-24 JP JP2006515402A patent/JP4779971B2/ja not_active Expired - Lifetime
- 2004-09-24 AT AT04773539T patent/ATE471740T1/de active
- 2004-09-24 US US10/948,288 patent/US7314862B2/en not_active Expired - Lifetime
- 2004-09-24 DE DE602004027824T patent/DE602004027824D1/de not_active Expired - Lifetime
- 2004-09-24 WO PCT/JP2004/014451 patent/WO2005030239A2/en not_active Ceased
2013
- 2013-09-09 CY CY20131100771T patent/CY1114359T1/el unknown

Also Published As

Publication number	Publication date
ATE471740T1 (de)	2010-07-15
CA2540108A1 (en)	2005-04-07
PL2263694T3 (pl)	2013-11-29
US7314862B2 (en)	2008-01-01
EP2263694A1 (en)	2010-12-22
EP1670514B1 (en)	2010-06-23
ES2344899T3 (es)	2010-09-09
CY1114359T1 (el)	2016-08-31
US20050070467A1 (en)	2005-03-31
ES2425083T3 (es)	2013-10-11
JP2007506647A (ja)	2007-03-22
MXPA06003222A (es)	2006-05-22
PT2263694E (pt)	2013-08-27
DK2263694T3 (da)	2013-08-26
EP1670514A2 (en)	2006-06-21
DE602004027824D1 (de)	2010-08-05
SI2263694T1 (sl)	2013-09-30
WO2005030239A3 (en)	2005-07-28
WO2005030239A2 (en)	2005-04-07
JP4779971B2 (ja)	2011-09-28
EP2263694B1 (en)	2013-06-12

Publication	Publication Date	Title
PL1670514T3 (pl)	2010-11-30	Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II
TW200738725A (en)	2007-10-16	Unsaturated mTOR inhibitors
TW200801006A (en)	2008-01-01	Fused bicyclic mTOR inhibitors
UA84712C2 (en)	2008-11-25	N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
JO2311B1 (en)	2005-09-12	Alkyl inhibitors Ariel phosphodiesterase-4
TW200626131A (en)	2006-08-01	C-aryl glucoside SGLT2 inhibitors and method
MY148688A (en)	2013-05-31	2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
SI1940786T1 (sl)	2010-11-30	Bifenilni derivati in njihova uporaba pri zdravljenju hepatitisa C
WO2009156735A3 (en)	2010-11-18	New therapeutic agents
TW200519111A (en)	2005-06-16	N3-substituted imidazopyridine C-KIT inhibitors
MX2009006742A (es)	2009-08-24	Inhibidores acilaminopirazoles como fgfr.
AU2002339157A1 (en)	2003-05-26	Inhibitors of the notch signalling pathway for use in the treatment of cancer
UA98141C2 (ru)	2012-04-25	Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
WO2003080582A3 (de)	2004-12-09	Fredericamycin-derivate
AU2002246728A1 (en)	2002-08-28	Carboline derivatives
AU2002364211A1 (en)	2003-07-15	Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2002340168A1 (en)	2003-06-17	Treatment of prostate cancer by inhibitors of ncam2
AU2002249890A1 (en)	2002-08-28	Carboline derivatives
MXPA03010761A (es)	2004-03-02	Combinaciones farmaceuticas.
UA96304C2 (en)	2011-10-25	2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
TW200508199A (en)	2005-03-01	Novel compound
IL174121A0 (en)	2006-08-01	Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
AU2002347747A1 (en)	2004-02-09	Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
WO2006055621A3 (en)	2006-08-17	Histone deacetylase inhibitors and methods of use
MX2007002600A (es)	2007-05-15	Mercaptoamidas como inhibidores de la histona deacetilasa.